Repligen (NASDAQ:RGEN) Trading Down 6.7% on Insider Selling

Shares of Repligen Corporation (NASDAQ:RGEN) dropped 6.7% on Monday after an insider sold shares in the company. The company traded as low as $136.61 and last traded at $137.1350. 771,221 shares traded hands during trading, a decline of 21% from the average daily volume of 980,143 shares. The stock had previously closed at $147.01.

Specifically, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. Royal Bank Of Canada assumed coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Roth Mkm began coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 target price on the stock. Jefferies Financial Group reissued a “hold” rating and set a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Wolfe Research initiated coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Finally, Rothschild & Co Redburn set a $160.00 price target on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Trading Down 6.7%

The firm has a fifty day moving average of $122.84 and a two-hundred day moving average of $135.36. The company has a market cap of $7.73 billion, a PE ratio of 152.30, a price-to-earnings-growth ratio of 2.83 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.99 EPS for the current year.

Institutional Trading of Repligen

A number of institutional investors have recently modified their holdings of the business. United Capital Financial Advisors LLC bought a new position in Repligen in the 3rd quarter worth approximately $368,387,000. Opti Capital Management LP bought a new stake in Repligen during the 4th quarter valued at $2,399,209,000. Maverick Capital Ltd. bought a new stake in Repligen during the 1st quarter valued at $178,946,000. Wasatch Advisors LP purchased a new stake in shares of Repligen during the first quarter worth $146,513,000. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of Repligen in the fourth quarter worth $199,176,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.